Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Growth of profitability and Core EPS Benefit from Ultomiris patent settlement and share repurchase Core operating profit Core EPS 40.2% 39.2% 37.9% % of sales CHFbn +9% at CER CHF 12.7 11.8 11.7 +11% at CER 10.44 10.56 11.76 CHFbn Operating free cash flow 30.3% 26.4% 17.2% 5.0 +21% at CER 8.1 9.8 Roche 2020 2021 2022 2020 2021 2022 2020 2021 2022 CER-Constant Exchange Rates 11

View entire presentation